Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Vertex said its profit fell due to higher operating expenses and a $379 million intangible asset impairment charge associated with treatment for Type 1 diabetes patients, which the company said in ...

Vertex, Inc. (VERX) kicks off 2025 strong with 12.9% revenue growth, strategic AI investments, and e-invoicing innovations.

Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference ...

A decade has passed since a short-lived railcar manufacturer opened its doors in Wilmington. At an invitation-only event in November 2014, many promises were made on behalf of Vertex Rail Technologies ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA ...